Fig. 1

LINC00183 promotes T-LBL progression and chemoresistance in vivo and in vitro. A The differential expression of lncRNAs in 3 remission and relapse tissues (left), and in 3 chemosensitivity and chemoresistance tissues (right). B Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) stratified by LINC00183 expression in T-LBL patients from the SYSUCC dataset. C Kaplan-Meier curves of PFS and OS stratified by LINC00183 expression in T-LBL patients from the AHAMU dataset. D MTT assays using T-LBL and LINC00183-overexpression T-LBL cells under the treatment of Dox (100ng/ml). E The protein expression of Bax, Bcl-2, caspase-3, and cleaved-caspase-3 in T-LBL and LINC00183-overexpression T-LBL cells treated with Dox (100ng/ml). F Flow cytometric analysis of T-LBL cells and LINC00183-overexpression T-LBL under the treatment of Dox (100ng/ml). G The tumor growth curve of mouse xenografts. The xenografts were formed SUP-T1 or SUP-T1-LINC00183 cells treated with Dox (1 mg/kg/time, 3 times/week). H The tumor size of mouse xenografts. I The protein expression of Bax, Bcl-2, and cleaved-caspase-3 in xenograft tissues. 3 xenografts tissues for each group. Dox, doxorubicin. LINC00183, ectopic LINC00183 expression in T-LBL cells. SUP-T1-LINC00183, SUP-T1 cells transfected with LINC00183. *, P < 0.05